Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876729 | PMC |
http://dx.doi.org/10.2967/jnumed.125.269538 | DOI Listing |
J Nucl Med
March 2025
Department of Radiology and Nuclear Medicine, Faculty of Medicine and Health Sciences, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Cancer Biother Radiopharm
May 2023
Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy.
In the past decade, the implementation of immunotherapy with checkpoint inhibitors has determined a major change in the management of oncological patients. The challenges associated to the new therapeutic regimen have promoted adapted criteria for response assessment to interpret imaging findings and atypical patterns of response. Parallel to the new morphological criteria, also fluoro-deoxyglucose positron emission/computed tomography imaging has required novel approaches and specific guidelines on how to perform, interpret, and report the scan in patients with solid tumors under immune checkpoint inhibitors therapy.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
April 2021
Department of Nuclear Medicine and Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Purpose: The aim of this EANM / SNMMI Practice Guideline with ESTRO endorsement is to provide general information and specific considerations about [F]FDG PET/CT in advanced uterine cervical cancer for external beam radiotherapy planning with emphasis on staging and target definition, mostly in FIGO stages IB3-IVA and IVB, treated with curative intention.
Methods: Guidelines from related fields, relevant literature and leading experts have been consulted during the development of this guideline. As this field is rapidly evolving, this guideline cannot be seen as definitive, nor is it a summary of all existing protocols.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!